Trending NewsTrending NewsLowest-Rated StocksLowest-RatedNASDAQ:YMAB Y-mAbs Therapeutics (YMAB) Stock Price, News & Analysis $8.52 0.00 (0.00%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$8.52 0.00 (-0.06%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Y-mAbs Therapeutics Stock (NASDAQ:YMAB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Y-mAbs Therapeutics alerts:Sign Up Key Stats Today's Range$8.51▼$8.5450-Day Range$4.19▼$8.5252-Week Range$3.55▼$16.11Volume1.24 million shsAverage Volume1.31 million shsMarket Capitalization$385.79 millionP/E RatioN/ADividend YieldN/APrice Target$11.16Consensus RatingHold Company Overview Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. Read More Y-mAbs Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreYMAB MarketRank™: Y-mAbs Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 496th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingY-mAbs Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on 1 buy rating, 8 hold ratings, and 2 sell ratings.Amount of Analyst CoverageY-mAbs Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Y-mAbs Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Y-mAbs Therapeutics are expected to grow in the coming year, from ($0.65) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Y-mAbs Therapeutics is -13.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Y-mAbs Therapeutics is -13.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioY-mAbs Therapeutics has a P/B Ratio of 4.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Y-mAbs Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.35% of the float of Y-mAbs Therapeutics has been sold short.Short Interest Ratio / Days to CoverY-mAbs Therapeutics has a short interest ratio ("days to cover") of 12.4, which indicates bearish sentiment.Change versus previous monthShort interest in Y-mAbs Therapeutics has recently increased by 80,222.58%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldY-mAbs Therapeutics does not currently pay a dividend.Dividend GrowthY-mAbs Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.35% of the float of Y-mAbs Therapeutics has been sold short.Short Interest Ratio / Days to CoverY-mAbs Therapeutics has a short interest ratio ("days to cover") of 12.4, which indicates bearish sentiment.Change versus previous monthShort interest in Y-mAbs Therapeutics has recently increased by 80,222.58%, indicating that investor sentiment is decreasing significantly. News and Social Media1.6 / 5News Sentiment-0.15 News SentimentY-mAbs Therapeutics has a news sentiment score of -0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Y-mAbs Therapeutics this week, compared to 4 articles on an average week.Search Interest1 people have searched for YMAB on MarketBeat in the last 30 days. MarketBeat FollowsOnly 5 people have added Y-mAbs Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -58% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Y-mAbs Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders19.70% of the stock of Y-mAbs Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.85% of the stock of Y-mAbs Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Y-mAbs Therapeutics' insider trading history. Receive YMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address YMAB Stock News HeadlinesY-mAbs Therapeutics (NASDAQ:YMAB) Given Neutral Rating at HC Wainwright2 hours ago | americanbankingnews.comY-mAbs Therapeutics (NASDAQ:YMAB) Stock Rating Lowered by Truist Financial2 hours ago | americanbankingnews.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI. | Brownstone Research (Ad)$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)August 7 at 6:44 PM | prnewswire.comY-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMABAugust 7 at 11:18 AM | businesswire.comY-mAbs Therapeutics, Inc. to Report Q2 2025 Financial Results on August 8, 2025, forgoing Earnings CallAugust 7 at 7:49 AM | quiverquant.comQY-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025August 7 at 7:30 AM | globenewswire.comHC Wainwright & Co. Downgrades Y-mAbs Therapeutics (YMAB)August 7 at 4:20 AM | msn.comSee More Headlines YMAB Stock Analysis - Frequently Asked Questions How have YMAB shares performed this year? Y-mAbs Therapeutics' stock was trading at $7.83 at the beginning of the year. Since then, YMAB stock has increased by 8.8% and is now trading at $8.52. How were Y-mAbs Therapeutics' earnings last quarter? Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) announced its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.10. The business had revenue of $20.90 million for the quarter, compared to analysts' expectations of $19.97 million. Y-mAbs Therapeutics had a negative net margin of 31.84% and a negative trailing twelve-month return on equity of 30.59%. Read the conference call transcript. When did Y-mAbs Therapeutics IPO? Y-mAbs Therapeutics (YMAB) raised $80 million in an IPO on Friday, September 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager. Who are Y-mAbs Therapeutics' major shareholders? Y-mAbs Therapeutics' top institutional shareholders include Los Angeles Capital Management LLC (0.02%) and CWM LLC (0.02%). Insiders that own company stock include Biotech Aps Wg, Johan Wedell-Wedellsborg, Bo Kruse, Thomas Gad, Michael J Rossi, Vignesh Rajah and Joris Wilms. View institutional ownership trends. How do I buy shares of Y-mAbs Therapeutics? Shares of YMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Y-mAbs Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Y-mAbs Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE) and Jabil (JBL). Company Calendar Last Earnings5/13/2025Today8/07/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:YMAB CIK1722964 Webwww.ymabs.com Phone(646) 885-8505FaxN/AEmployees150Year FoundedN/APrice Target and Rating Average Price Target for Y-mAbs Therapeutics$11.16 High Price Target$25.00 Low Price Target$3.00 Potential Upside/Downside+31.0%Consensus RatingHold Rating Score (0-4)2.08 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$29.67 million Net Margins-31.84% Pretax Margin-32.18% Return on Equity-30.59% Return on Assets-22.70% Debt Debt-to-Equity RatioN/A Current Ratio4.77 Quick Ratio4.35 Sales & Book Value Annual Sales$87.68 million Price / Sales4.40 Cash FlowN/A Price / Cash FlowN/A Book Value$2.05 per share Price / Book4.16Miscellaneous Outstanding Shares45,280,000Free Float36,363,000Market Cap$385.79 million OptionableOptionable Beta0.57 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:YMAB) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Y-mAbs Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
